ADMA Biologics - ADMA Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings or view top-rated stocks.

2 analysts have issued 1 year price targets for ADMA Biologics' stock. Their ADMA share price forecasts range from $4.50 to $6.00. On average, they predict the company's stock price to reach $5.25 in the next twelve months. This suggests a possible upside of 60.6% from the stock's current price.
View analysts price targets for ADMA or view top-rated stocks among Wall Street analysts.

ADMA Biologics' stock was trading at $3.88 at the beginning of 2023. Since then, ADMA stock has decreased by 15.7% and is now trading at $3.27.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our ADMA earnings forecast.

ADMA Biologics, Inc. (NASDAQ:ADMA) announced its quarterly earnings results on Thursday, March, 23rd. The biotechnology company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). The biotechnology company had revenue of $49.98 million for the quarter, compared to analyst estimates of $49.02 million. ADMA Biologics had a negative trailing twelve-month return on equity of 47.99% and a negative net margin of 42.77%. During the same period in the prior year, the firm posted ($0.09) earnings per share.

ETFs with the largest weight of ADMA Biologics (NASDAQ:ADMA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Invesco Raymond James SB-1 Equity ETF (RYJ), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), Vanguard U.S. Momentum Factor ETF (VFMO), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

ADMA Biologics updated its FY 2023 earnings guidance on Thursday, March, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $210.00M-, compared to the consensus revenue estimate of $202.75 million.

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

ADMA Biologics' stock is owned by many different institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (3.53%), AWM Investment Company Inc. (3.06%), Millennium Management LLC (2.69%), Geode Capital Management LLC (1.72%), Morgan Stanley (1.64%) and Caligan Partners LP (1.36%). Insiders that own company stock include Adam S Grossman, Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Perceptive Advisors Llc and Young Kwon.
View institutional ownership trends.

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADMA stock can currently be purchased for approximately $3.27.

ADMA Biologics (NASDAQ:ADMA) has a market capitalization of $643.47 million and generates $154.08 million in revenue each year. The biotechnology company earns $-65,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

The company employs 527 workers across the globe.

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The official website for the company is www.admabiologics.com. The biotechnology company can be reached via phone at (201) 478-5552, via email at info@admabio.com, or via fax at 201-478-5553.